Shots:
- The US FDA has approved Qfitlia to treat routine prophylaxis and prevent or reduce the frequency of bleeding episodes in pts. (age≥ 12yrs.) with hemophilia A or B, with or without factor VIII or IX inhibitors. Regulatory submissions have been completed in China & Brazil
- Qfitlia published clinical data in the NEJM in 2017, showing a reduction in bleeding rates in haemophilia pts. and initiating the P-III development program
- In 2014, Sanofi gained global rights to co-develop & co-commercialize Qfitlia under a license & collaboration agreement which was later upgraded to full global rights in 2018, while Alnylam became eligible for tiered royalties of 15-30% on global net sales
Ref: Businesswire | Image: Alnylam & Sanofi
Related News:- Alnylam Pharmaceuticals Reports the US FDA’s Approval of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
